Etanercept in psoriasis
- PMID: 15461549
- DOI: 10.1517/14656566.5.10.2139
Etanercept in psoriasis
Abstract
Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European populations. Several lines of evidence have demonstrated the correlation between elevated levels of TNF and psoriasis, suggesting that interfering with the inflammatory effects of TNF may help resolve psoriatic lesions. The biological agent, etanercept, is a fully human soluble TNF-receptor fusion protein with proven efficacy in the treatment of rheumatoid arthritis, ankylosing spondylitis, juvenile rheumatoid arthritis, and psoriatic arthritis. In several well-controlled clinical trials, etanercept showed sustained efficacy in reducing the signs and symptoms of psoriasis in patients with moderate-to-severe disease. With the exception of injection site reactions, adverse event rates were similar to placebo and did not increase across higher doses. No opportunistic infections, including tuberculosis, were reported. From analysis of the available clinical trials, etanercept appears to be an effective and well-tolerated agent for the treatment of moderate-to-severe psoriasis.
Similar articles
-
Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.Skin Therapy Lett. 2003 Jan;8(1):1-4. Skin Therapy Lett. 2003. PMID: 12728284 Clinical Trial.
-
Etanercept: efficacy and safety for approved indications.Expert Opin Drug Saf. 2012 Jan;11(1):121-39. doi: 10.1517/14740338.2012.633509. Epub 2011 Nov 11. Expert Opin Drug Saf. 2012. PMID: 22074366 Review.
-
TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.BioDrugs. 2005;19(1):47-57. doi: 10.2165/00063030-200519010-00006. BioDrugs. 2005. PMID: 15691217 Review.
-
Etanercept.Expert Opin Biol Ther. 2008 Apr;8(4):491-502. doi: 10.1517/14712598.8.4.491. Expert Opin Biol Ther. 2008. PMID: 18352852 Review.
-
Two years of experience with etanercept in recalcitrant psoriasis.Br J Dermatol. 2007 May;156(5):1010-4. doi: 10.1111/j.1365-2133.2007.07829.x. Epub 2007 Apr 4. Br J Dermatol. 2007. PMID: 17408393
Cited by
-
Etanercept in the treatment of plaque psoriasis.Clin Cosmet Investig Dermatol. 2009 May 19;2:77-84. doi: 10.2147/ccid.s3412. Clin Cosmet Investig Dermatol. 2009. PMID: 21436970 Free PMC article.
-
The safety of etanercept for the treatment of plaque psoriasis.Ther Clin Risk Manag. 2007 Jun;3(2):245-58. doi: 10.2147/tcrm.2007.3.2.245. Ther Clin Risk Manag. 2007. PMID: 18360633 Free PMC article.
-
Secondary Generalized Cutaneous Mucinosis Developed During Etanercept Treatment in a Patient with Psoriasis.Clin Cosmet Investig Dermatol. 2022 May 31;15:987-992. doi: 10.2147/CCID.S368390. eCollection 2022. Clin Cosmet Investig Dermatol. 2022. PMID: 35669090 Free PMC article.
-
Effect of TNF-α inhibitors on transcriptional levels of pro-inflammatory interleukin-33 and Toll-like receptors-2 and -9 in psoriatic plaques.Exp Ther Med. 2015 Oct;10(4):1573-1577. doi: 10.3892/etm.2015.2688. Epub 2015 Aug 18. Exp Ther Med. 2015. PMID: 26622528 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials